- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Submit a Manuscript
- Table of Contents
Case Reports in Obstetrics and Gynecology
Volume 2012 (2012), Article ID 314535, 3 pages
doi:10.1155/2012/314535
Squamous Cell Carcinoma Arising in a Mature Cystic Teratoma
1Division of Internal Medicine, Sisli Education and Research Hospital, 34200 Istanbul, Turkey
2Division of Medical Oncology, Department of Internal Medicine, Sisli Education and Research Hospital, 34200 Istanbul, Turkey
3Division of Pathology, Sisli Education and Research Hospital, 34200 Istanbul, Turkey
Received 7 November 2012; Accepted 9 December 2012
Academic Editors: C. Ficicioglu and B. Piura
Copyright © 2012 Suna Avcı et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction. Malignant transformation in a mature cystic teratoma of the ovary is a rare complication. Squamous cell carcinoma is the most common transformation. We describe a new case of squamous cell carcinoma arising in a mature cystic teratoma. Case Report. A premenopausal 52-year-old female patient is diagnosed with vaginal bleeding. According to examination made on the women and the pelvic scanning, 7 cm mass is found on the right adnexa of the patient. Total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, pelvic lymph node dissection, and debulking were the treatments completed on the patient. According to histopathological diagnosis, squamous cell carcinoma arising in a mature cystic teratoma is diagnosed as a reason for the mass in the right adnexa of the patient. Conclusion. The prognosis of the malign transformation of MCT depends on surgery stage; however it is extremely poor. The patient should receive chemotherapy regardless of stage. We have decided to administer second cycle carboplatin and paclitaxel treatments on the patient.